WASHINGTON, Aug. 3, 2011 /PRNewswire-USNewswire/ — The National
Pharmaceutical Council (NPC) today welcomed global specialty
biopharmaceutical company Shire plc as a new member. Dr. Jeffrey M.
Jonas, senior vice president, specialty pharma R&D, will serve
as Shire’s representative on the NPC board of directors.
“The last few years have brought change to the health care
environment that has left many important questions unresolved.
For the pharmaceutical industry, how comparative
effectiveness research will be conducted and used is critical.
We welcome Shire and look forward to their contribution to our
shared mission of helping to answer these questions and chart the
future,” said NPC President Dan Leonard.
Shire, with facilities in Pennsylvania and Massachusetts, is
focused on attention deficit hyperactivity disorder (ADHD), human
genetic therapies (HGT) and gastrointestinal (GI) diseases as well
as opportunities in other therapeutic areas to the extent they
arise through acquisitions. Shire’s in-licensing, merger and
acquisition efforts are focused on products in specialist markets
with strong intellectual property protection and global
“Shire is very supportive of NPC’s focus on evidence-based
medicine and on policy research related to comparative
effectiveness research, pharmaceutical innovation and the value of
medicines,” said Dr. Jonas. “We’re pleased to be a part of this
organization and look forward to working with NPC on issues
affecting the pharmaceutical industry.”
an NPC member, Shire joins with other leading research-based
pharmaceutical companies, including Abbott Laboratories, Astra
Zeneca LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim
Pharmaceuticals Inc., Bristol-Myers Squibb Company, Daiichi Sankyo,
Inc., Eisai inc., GlaxoSmi